SLC5A2 and diabetes mellitus: An additional 18% of physicians (24/197 endocrinologists and 48/203 PCPs) indicated that while they would not prescribe SGLT2 inhibitors in type 2 diabetes mellitus patients at low risk of diabetic kidney disease, they would order SGLT2 inhibitors for their patients at an increased risk of diabetic kidney disease.